Chemists track how drug changes, blocks flu virus

An anti-virus drug attacks influenza A by changing the motion and structure of a proton channel necessary for the virus to infect healthy cells, according to a recently published research paper by two Iowa State University chemists.

Mei Hong, Iowa State’s John D. Corbett Professor in Chemistry, and Sarah Cady, a graduate student in chemistry, are studying the effects of the antiviral drug amantadine on influenza A. That’s the type of flu bug that most commonly makes people sick and the one that has caused the most serious flu epidemics.

Their findings appear in the Feb. 5 edition of the Proceedings of the National Academy of Sciences.

Hong said the findings are particularly important because mutations of the type A virus are resistant to amantadine treatment.

“In the last few years, amantadine resistance has skyrocketed among influenza A viruses in Asia and North America, making it imperative to develop alternative antiviral drugs,” Hong and Cady wrote in their paper.

To develop those drugs, Hong said researchers first need to understand exactly how amantadine stops the flu virus.

First, some background about how a flu virus infects a healthy cell: A virus begins the process by attaching itself to a healthy cell. The healthy cell surrounds the flu virus and takes it inside the cell through a process called endocytosis. Once in the cell, the virus uses a protein called M2 to open a channel to the healthy cell. Protons from the healthy cell flow through the channel into the virus and raise its acidity. That triggers the release of the virus’ genetic material into the healthy cell. The virus hijacks the healthy cell’s resources and uses them to reproduce and spread the virus.

If the M2 proton channel is blocked, the process doesn’t work and a virus can’t infect a cell and spread.

Hong and Cady studied the proton channel with the help of solid-state nuclear magnetic resonance spectroscopy – a technique similar to the magnetic resonance imaging technology that takes pictures of soft tissues in the body. The technology enabled them to discover and describe the motion and structure of the M2 proton channel in virus cells. They studied the channel when cells were treated with amantadine and when they were not.

Hong said the study made three findings:

-- First, the M2 protein is in constant motion, changing among various conformations, and amantadine treatment changes the rate of motion and reduces the number of possible conformations the protein can adopt.

-- Second, the structure of the protein changes most prominently at two places facing the channel interior when cells are treated with amantadine.

-- And third, the tilt and orientation of the protein’s helices are subtly changed by amantadine.

And all that blocks the ability of a virus to infect a healthy cell.

“We didn’t know that before,” Hong said. “And now that makes it very clear what we should study next.”

Hong’s next step is to examine how mutant versions of the virus are able to resist the flu-stopping changes caused by amantadine. Hong said that study will depend on winning research funding and recruiting graduate students interested in chemistry with biological applications.

Source: Iowa State University

Related stories:

Researchers Race to Design the First Treatments Specifically for NeuroAIDS
Experimental drugs are showing promise against neuroAIDS, the nerve damage caused by HIV infection that lessens many patients’ ability to think and move. As evidence of the progress, researchers at the University of Rochester Medical Center today received a $7 million grant to confirm that two new drug classes can protect the brain from HIV-related nerve damage. Driving their approach is the realization that antiviral drugs that work against AIDS do not cure neuroAIDS.
Zinc finger proteins put personalized HIV therapy within reach
Researchers at the University of Pennsylvania School of Medicine and collaborators are using minute, naturally occurring proteins called zinc fingers to engineer T cells to one day treat AIDS in humans.
UC researchers find new ways to regulate genes, reduce heart damage
Researchers at the University of Cincinnati (UC) are looking for ways to reduce or prevent heart damage by starting where the problem often begins: in the genes.
Effective health messages may yield vaccine compliance among ER workers
Emergency room workers will be the first line of defense in the event of a disease pandemic and will be forced to deal with the chaos that inevitably comes with treating thousands of sick and dying. In order to protect themselves and allow them to care for the public, these first responders need to be fully prepared by getting available vaccines now.
Cell surface receptors are all 'talk' in T cell stimulation
Understanding the mechanisms that drive healthy immune responses is important when it comes to combating autoimmune diseases, which occur when cells that should attack invading organisms turn on the body instead.
Gene therapy slows progression of Batten Disease
Gene therapy that helps defective brain cells get rid of "garbage" appears both safe and effective at slowing down Batten disease, according to promising findings from NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
Rapid escalation characterizes virus/host arms race
The interaction between a virus and its host is often portrayed as an arms race, with each new viral attack parried by the host and each new defense by the host one-upped by the virus.
Study finds unique HIV vaccine formula elicits strong immune responses
Today, Advanced BioScience Laboratories, Inc. and the University of Massachusetts Medical School report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.

News discussion:

General Science news